Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Cancer, Lipids, and Metabolism, and Radiopharmaceutical Chemistry and Applications.
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.
The potential of multi-cancer early detection screening in reducing cancer incidence and mortality in high-risk groups: A modeling study.
The impact of multicancer early detection tests on cancer stage shift: A 10‐year microsimulation model
A decade of progress: Trends in 5-year survival across 17 cancer types.
Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study.
Tumor localization strategies of multicancer early detection tests: a quantitative assessment.
Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-Based Tests for Early Cancer Detection.
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry.
Supplementary Table 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Supplementary Table 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Data from Dying To Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era
Supplementary Data 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Supplementary Table 3. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Supplementary Figure 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Supplementary Figure 7. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
TMPRSS2 Expression in Lung Tissue of Prostatic Adenocarcinoma Patients: A Pathologic Perspective on Androgen Deprivation Therapy
Supplementary Figure 5. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Supplementary Figure 3. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Supplementary Table S1 from Dying To Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era
Supplementary Figure 6. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Supplementary Figure 4. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Supplementary Data 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Supplementary Figure 8. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Supplementary Figure 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
Multiyear Clinical Outcomes of Cancers Diagnosed Following Detection by a Blood-Based Multicancer Early Detection Test.
Outcomes Following a False-Positive Multi-Cancer Early Detection Test: Results from DETECT-A, the First Large, Prospective, Interventional MCED Study.
Comparative Transcriptomes of Canine and Human Prostate Cancers Identify Mediators of Castration Resistance.
Effect of multi-cancer early detection screening on late-stage cancers: A modeling study.